The University of Rochester Medical Center, in collaboration with Rochester Regional Health, delivered the country’s first doses of a potential COVID-19 vaccine to volunteers. This is a final stage of the national trial prior to FDA approval.
In May, URMC began participating in phase 1 trials of the vaccine candidates. Rochester was one of only four sites in the U.S. involved in this early stage study.
“Rochester has a long history of national leadership in vaccine development, the study of emerging infectious diseases, and understanding how the human immune system reacts to infection,” says Ann R. Falsey, M.D., co-director of the URMC Vaccine and Treatment Evaluation Clinic.